Dara L. Aisner

22.3k total citations · 4 hit papers
134 papers, 8.5k citations indexed

About

Dara L. Aisner is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Dara L. Aisner has authored 134 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Pulmonary and Respiratory Medicine, 62 papers in Oncology and 49 papers in Molecular Biology. Recurrent topics in Dara L. Aisner's work include Lung Cancer Treatments and Mutations (74 papers), Cancer Genomics and Diagnostics (34 papers) and Lung Cancer Research Studies (24 papers). Dara L. Aisner is often cited by papers focused on Lung Cancer Treatments and Mutations (74 papers), Cancer Genomics and Diagnostics (34 papers) and Lung Cancer Research Studies (24 papers). Dara L. Aisner collaborates with scholars based in United States, Canada and Italy. Dara L. Aisner's co-authors include Robert C. Doebele, D. Ross Camidge, Marileila Varella‐Garcia, Anh T. Le, J. Michael McGinnis, Paul A. Bunn, Andrew Weickhardt, LeighAnne Olsen, Jerry W. Shay and Woodring E. Wright and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Dara L. Aisner

129 papers receiving 8.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

2012 820 citations Robert C. Doebele, Amanda Pilling et al. Clinical Cancer Research profile →
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

2012 508 citations Andrew Weickhardt, Gregory N. Gan et al. Journal of Thoracic Oncology profile →
The Learning Healthcare System: Workshop Summary

2013 369 citations Dara L. Aisner et al. profile →
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

2015 302 citations Robert C. Doebele, Lara E. Davis et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dara L. Aisner United States	51	4.8k	3.7k	3.5k	1.8k	895	134	8.5k
Siqing Fu United States	51	2.4k 0.5×	4.1k 1.1×	3.8k 1.1×	2.4k 1.3×	293 0.3×	412	9.6k
John A. Thompson United States	43	4.3k 0.9×	5.7k 1.5×	5.0k 1.4×	2.2k 1.2×	282 0.3×	123	11.2k
Anthony Elias United States	50	3.5k 0.7×	5.9k 1.6×	2.2k 0.6×	2.0k 1.1×	257 0.3×	205	9.8k
Emilio Bria Italy	46	2.8k 0.6×	4.0k 1.1×	1.8k 0.5×	1.5k 0.8×	495 0.6×	392	7.1k
Alberto Ocaña Spain	51	2.5k 0.5×	7.3k 2.0×	3.8k 1.1×	2.5k 1.4×	274 0.3×	302	12.3k
Gideon M. Blumenthal United States	47	2.6k 0.5×	4.0k 1.1×	2.4k 0.7×	1.3k 0.7×	221 0.2×	119	7.5k
Edward S. Kim United States	52	5.3k 1.1×	5.2k 1.4×	2.9k 0.8×	1.9k 1.0×	162 0.2×	216	9.8k
Sabino De Placido Italy	64	4.5k 0.9×	7.8k 2.1×	4.4k 1.3×	3.7k 2.0×	261 0.3×	381	14.0k
David E. Gerber United States	49	4.4k 0.9×	5.4k 1.4×	1.8k 0.5×	1.1k 0.6×	196 0.2×	292	9.6k
Hal W. Hirte Canada	45	1.3k 0.3×	3.7k 1.0×	3.2k 0.9×	977 0.5×	762 0.9×	156	8.1k

Countries citing papers authored by Dara L. Aisner

Since Specialization

Citations

This map shows the geographic impact of Dara L. Aisner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dara L. Aisner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dara L. Aisner more than expected).

Fields of papers citing papers by Dara L. Aisner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dara L. Aisner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dara L. Aisner. The network helps show where Dara L. Aisner may publish in the future.

Co-authorship network of co-authors of Dara L. Aisner

This figure shows the co-authorship network connecting the top 25 collaborators of Dara L. Aisner. A scholar is included among the top collaborators of Dara L. Aisner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dara L. Aisner. Dara L. Aisner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Davies, Kurtis D., et al.. (2024). Clinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an EGFR::ERBB4 Fusion Through Use of EGFR Tyrosine Kinase Inhibitors. JCO Precision Oncology. 8(8). e2400526–e2400526. 1 indexed citations

Esplin, Edward D., Sarah Young, Emily M. Russell, et al.. (2024). Smoking and pathogenic germline variants in patients with lung cancer.. Journal of Clinical Oncology. 42(16_suppl). 8040–8040.

Marmarelis, Melina E., Caroline E. McCoach, Geoffrey Liu, et al.. (2023). Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC).. Journal of Clinical Oncology. 41(16_suppl). 9116–9116.

Borges, Virginia F., et al.. (2022). PIK3CAMutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. JCO Precision Oncology. 6(6). e2100370–e2100370. 37 indexed citations

McCoach, Caroline E., Anh T. Le, Katherine Gowan, et al.. (2018). Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer. Clinical Cancer Research. 24(14). 3334–3347. 179 indexed citations

Karam, Sana D., Krishna Reddy, Patrick J. Blatchford, et al.. (2018). Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clinical Cancer Research. 24(20). 4949–4959. 68 indexed citations

McCoach, Caroline E., Collin M. Blakely, Kimberly C. Banks, et al.. (2018). Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer. Clinical Cancer Research. 24(12). 2758–2770. 114 indexed citations

Vaishnavi, Aria, Laura Schubert, Uwe Rix, et al.. (2017). EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Research. 77(13). 3551–3563. 61 indexed citations

Aisner, Dara L., Anna B. Berry, D. Brian Dawson, et al.. (2016). A Suggested Molecular Pathology Curriculum for Residents. Journal of Molecular Diagnostics. 18(2). 153–162. 9 indexed citations

10.

Noonan, Sinéad, Lynne D. Berry, Xian Lu, et al.. (2016). Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. Journal of Thoracic Oncology. 11(8). 1293–1304. 126 indexed citations

11.

Doebele, Robert C., Lara E. Davis, Aria Vaishnavi, et al.. (2015). An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discovery. 5(10). 1049–1057. 302 indexed citations breakdown →

12.

Li, Bob T., Dara S. Ross, Dara L. Aisner, et al.. (2015). HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. Journal of Thoracic Oncology. 11(3). 414–419. 212 indexed citations

13.

Bowles, Daniel W., Jennifer R. Diamond, Elaine T. Lam, et al.. (2014). Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies. Clinical Cancer Research. 20(6). 1656–1665. 54 indexed citations

14.

Ren, Shengxiang, Fred R. Hirsch, Marileila Varella‐Garcia, et al.. (2014). Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(3). e21–e23. 50 indexed citations

15.

Anderson, Ryan T., Stephen B. Keysar, Daniel W. Bowles, et al.. (2013). The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas. Molecular Cancer Therapeutics. 12(10). 1994–2005. 20 indexed citations

16.

Bennati, Chiara, Dara L. Aisner, Rita Chiari, et al.. (2013). Identification of Targetable Driver Mutations In Molecularly Selected Never Smoker Lung Adenocarcinomas. Journal of Thoracic Oncology. 8. 1 indexed citations

17.

Doebele, Robert C., Amanda Pilling, Dara L. Aisner, et al.. (2012). Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer. Clinical Cancer Research. 18(5). 1472–1482. 820 indexed citations breakdown →

18.

Davies, Kurtis D., Anh T. Le, Mariana F. Theodoro, et al.. (2012). Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer. Clinical Cancer Research. 18(17). 4570–4579. 330 indexed citations

19.

Zuna, Rosemary E., R Allen, William Moore, et al.. (2005). Dermatopathology. Laboratory Investigation. 85. 82–88. 2 indexed citations

20.

Aisner, Dara L.. (2002). Telomerase regulation: not just flipping the switch. Current Opinion in Genetics & Development. 12(1). 80–85. 125 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact